Remodeling of filamentous actin into distinct arrangements is precisely controlled by members of the
Results and discussion
Activation of the small GTPase RhoA induces a number of morphological events including the promotion of stress fibers, an increase in focal adhesions and cell contractility [2] . Serum-starved Swiss 3T3 fibroblasts treated with calpeptin undergo actin reorganization reminiscent of a RhoA phenotype ( [5] , and Figure 1a ). Our previous studies have shown that calpeptin-mediated cytoskeletal effects are induced through inhibition of one or more PTPase(s) situated upstream of RhoA [5] . To determine if calpeptinsensitive PTPase(s) regulate RhoA activity, we constructed a glutathione S-transferase (GST) fusion protein comprising the RhoA-binding domain (RBD) of Rhotekin (an effector for RhoA), similar to that described previously [6] . This GST fusion protein specifically binds to the active GTP-bound form of RhoA. Analysis of cell lysates treated with calpeptin (100 µg/ml) revealed that this peptide promotes the accumulation of active (GTP-bound) RhoA (Figure 1b) , confirming that calpeptin increases the level of active RhoA. Similar studies examining the effect of calpeptin on the activity of other Rho-family GTPases revealed no changes in GTP loading of either Rac or Cdc42 (Figure 1b) , demonstrating that calpeptin-sensitive PTPase(s) specifically modulate RhoA activity.
To identify potential calpeptin-sensitive PTPase(s) responsible for regulation of RhoA, we developed an immobilized form of this peptide inhibitor (Figure 2a ). Initial analysis of overall PTPase activity precipitated with immobilized calpeptin, using an in-gel PTPase assay, revealed two major PTPases of ~70 and 120-130 kDa (data not shown). Only the PTPase activity migrating at Calpeptin-sensitive PTPase(s) regulate the activity of RhoA. (a) Swiss 3T3 fibroblasts were serum-starved for 24 h, to induce disassembly of the cytoskeleton [5] . Cells were incubated with serum-free medium in the presence or absence of calpeptin (100 µg/ml) for 30 min, and stained for actin with rhodamine-conjugated phalloidin. (b) The levels of active RhoA, Rac or Cdc42 in REF-52 fibroblasts treated with vehicle alone (C) or 100 µg/ml calpeptin (CP) (30 min) were analyzed by precipitating GTPbound RhoA with GST-RBD, or GTP-bound Rac and Cdc42 using GST-PBD (see Materials and methods). Proteins precipitating with GST fusion proteins were analyzed by immunoblotting with monoclonal antibodies recognizing RhoA, Rac or Cdc42. 70 kDa specifically bound to immobilized calpeptin, and not to the control resin. Immunoblot analysis demonstrated that the calpeptin-bound activity migrating at approximately 70 kDa was Shp-2, a previously described SH2-containing PTPase [7, 8] . Further analysis confirmed that Shp-2 bound to immobilized calpeptin but not to control beads (Figure 2b) , and also demonstrated that binding was significantly reduced in the presence of soluble calpeptin (data not shown), confirming the association of Shp-2 with this peptide. Additional immunoblot analysis of calpeptin-binding proteins revealed that immobilized calpeptin did not precipitate PTPα or PTP-1B (Figure 2b ). We also assessed the ability of the hematopoietic-specific Shp-1, which belongs to the family of SH2-containing PTPases, to associate with immobilized calpeptin. Despite its similarity to Shp-2, we could not detect any binding of this PTPase to the immobilized peptide ( Figure 2b ). While these studies do not rule out the possibility that other PTPases may associate with calpeptin, they do identify Shp-2 as a potential calpeptinsensitive PTPase.
To demonstrate that the binding of calpeptin to Shp-2 has physiological consequences, we analyzed the effect of this inhibitor on Shp-2 signaling. In vitro PTPase assays using a GST fusion protein comprising the catalytic domain of Shp-2 were performed in the presence or absence of increasing amounts of calpeptin. We found the effect of calpeptin to be dose-dependent, with 100 µg/ml of calpeptin decreasing activity of this PTPase by approximately 40%, whereas higher concentrations (1.0 mg/ml) inhibited Shp-2 activity by approximately 90% (Figure 2c ). The ability of calpeptin to inhibit Shp-2 PTPase activity in vivo was also examined, by analyzing the effect of this inhibitor on established Shp-2 signaling pathways. Previous studies have shown that abrogation of this PTPase results in modulation of Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) signaling [9] . Examination of calpeptin-treated cells for JNK activation revealed a rise in the phosphorylation of JNK (consistent with its activation), in both HeLa cells (data not shown) and REF-52 fibroblasts (Figure 2d ), similar to the elevated JNK activity seen in Shp-2 mutant cells [9] . In contrast to its effect on JNK activity, Shp-2 has been reported to reduce and/or delay the level of ERK activation in response to growth factors or phorbol myristoyl acetate (PMA) [9] . Consistent with this, REF-52 fibroblasts treated with calpeptin show a reduction in sustained ERK activation in response to PMA (see Supplementary material). These findings are consistent with calpeptin's ability to inhibit Shp-2.
The observations presented above raise the possibility that Shp-2 may be the calpeptin-sensitive PTPase involved in the regulation of RhoA activity. To investigate this hypothesis, we analyzed the morphology and level of RhoA activity in embryonic fibroblasts derived from mice with a targeted disruption in exon 3 of the Shp-2 gene (Shp-2 ∆46-110 ). These cells express a truncated Shp-2 lacking its amino-terminal SH2 domain, at a greatly reduced level when compared to the full-length wild-type PTPase [9] . Thus far, evidence suggests that the ∆46-110 Shp-2 mutation might behave as a loss-of-function mutant in cells.
Comparison of these fibroblasts with wild-type cells revealed an increase in the level of GTP-bound RhoA in the mutant (Shp-2 ∆46-110 )-expressing cells (Figure 3a , left panels), concomitant with an increase in F-actin staining [10] . Re-expression of wild-type Shp-2 in Shp-2 ∆46-110 mutant cells (Shp-2 rescue ) decreased RhoA-GTP levels when compared with expression of vector alone (Shp-2 ∆46-110 ; Figure 3a , middle panels) and reduced the level of F-actin staining in these cells (see Supplemetary material). Furthermore, Shp-2 ∆46-110 fibroblasts were less responsive to changes in actin reorganization (see Supplementary material) and Rho-GTP levels ( Figure 3b , third and fourth panels) when challenged with calpeptin, an effect which This suggests that Shp-2 inhibition is mediating the calpeptin-induced effects on RhoA activity. We also examined RhoA activity levels in CHO cells transiently transfected with dominant-negative Shp-2 (CHO SH2 ). Consistent with our previous results in mouse fibroblasts, CHO SH2 cells exhibited elevated RhoA-GTP levels ( Figure 3a , right panels), when compared with cells transfected with vector alone (CHO vector ). As with Shp-2 ∆46-110 mutant cells, the response of CHO SH2 cells to calpeptin was significantly reduced (Figure 3b , first and second panels). These results support our hypothesis that Shp-2 negatively regulates RhoA activity.
The concerted actions of Rho proteins on the arrangement of F-actin influence numerous normal and pathological events including embryonic development, wound healing and tumor metastasis [1] . Many of these processes rely critically on cell migration. RhoA is required for the characteristic formation and maintenance of stress fibers and focal adhesions, but it is also required to maintain a certain level of cell adhesion during cell movement [3] . Concordant with this, our studies show that inhibition of Shp-2 effectively increases the basal level of active RhoA, thereby increasing cell adhesion. Excessive levels of cell adhesion would be expected to negatively affect cell motility, preventing cells from releasing their contact sites as they attempt to migrate across an extracellular matrix. This hypothesis is consistent with several studies that have investigated the biological function of Shp-2 [10] [11] [12] [13] [14] [15] [16] . Animals with dysfunctional Shp-2 die at mid-gestation with severe defects in mesodermal patterning and body organization [11] . These mutant embryos fail to undergo morphogenetic movements at gastrulation [15, 16] . Cells derived from these embryos exhibit increased focal adhesions, and decreased cell spreading and migration [10] , which is also consistent with an increase in RhoA activation. We suggest that abrogation of Shp-2 in these embryos raises the basal level of RhoA activity, thereby impairing migration and contributing to the observed migration-based embryonic defects.
We have shown that Shp-2 is an important regulatory component upstream of the small GTPase RhoA. Although our studies indicate that Shp-2 regulates RhoA, the substrates that are dephosphorylated by Shp-2 are currently under investigation. Interestingly, there is now a precedent for the activation of guanine-nucleotide exchange factors (GEF), which facilitate nucleotide exchange on Rho family proteins, by tyrosine phosphorylation [4] . In addition, tyrosine phosphorylation of GTPase-activating proteins (GAPs), which stimulate the intrinsic GAP activity of small GTPases, have also been reported [17] . With p190RhoGAP, however, increased tyrosine phosphorylation is correlated with increased GAP activity, and consequently decreased RhoA-GTP levels [18] .
Ligation of several growth factor receptors results in a loss of stress fibers and focal adhesions, indicative of decreased Brief Communication 1525 RhoA activity [4] . One mechanism contributing to this effect is suggested by our findings here that Shp-2 negatively regulates RhoA activity. We envisage a model wherein recruitment of Shp-2 by growth factor receptors brings this PTPase into close proximity with a critical RhoA GEF (see Supplementary material). Dephosphorylation of the GEF by Shp-2 downregulates its activity, resulting in decreased RhoA-GTP levels, in turn leading to a loss of stress fibers and focal adhesions, and effects on the motile state of the cell.
Materials and methods

Cell lines, antibodies and constructs
Shp-2 wild-type (Shp-2 WT ) , mutant (Shp-2 ∆46-110 ) and Shp-2 ∆46-110 rescued with wild-type Shp-2 (Shp-2 rescue ) embryonic fibroblast cell lines were established from E9.5 mouse embryos as described ( [9, 10] and Supplementary material). Transient transfection of CHO cells was carried out using LipofectAMINE PLUS reagent (Gibco BRL), according to manufacturers instructions (see Supplementary material). The plasmid containing cDNA encoding Shp-2 SH2 domains (dominant negative) was generated as previously described [19] . Activation-specific anti-SAPK/JNK polyclonal antibody was from New England BioLabs. Phospho-specific anti-ERK monoclonal antibody was from UBI. All other monoclonal antibodies were purchased from Transduction Laboratories.
Preparation and use of immobilized calpeptin
The reactive portion of calpeptin (Leu-Nle-CHO) was synthesized commercially (SynPep Corporation), and coupled to Affi-Gel10 resin (0.5 mg peptide per ml resin) (BioRad). Affi-Gel10 control resin was prepared by blocking active esters, according to the manufacturer's instructions. Cells lysed in a Triton X-100-containing lysis buffer (10 mM Tris pH 7.6, 150 mM NaCl, 1% Triton X-100, 2 mM MgCl 2 , 2 mM EGTA, 0.1 mM DTT, 10 µg/ml aprotinin) were incubated with immobilized calpeptin or control resin for 2 h at 4°C, and beads washed with lysis buffer. Precipitated proteins were analyzed by SDS-PAGE and immunoblot analysis.
In vitro PTPase assays
The catalytic domain of wild-type Shp-2 was generated by PCR amplification of a cDNA fragment coding for amino acids 217-585 of Shp-2 and cloning into pGex2T vector via BamH1 and EcoR1. The resulting GST fusion protein was expressed in BL21 cells and purified as described previously [5] . PTPase assays were performed essentially as described [20] , using p-nitrophenyl phosphate as a substrate.
Assay for GTP-bound RhoA, Rac and Cdc42
The RhoA-binding domain (RBD) of Rhotekin (amino acids 7-89) was amplified from cDNA prepared from BALB 3T3 mRNA, and cloned into the pGEX-2T vector. The Rac/Cdc42-binding domain of PAK (PBD) was a kind gift from R.A. Cerione (Cornell University, New York). Both RBD and PBD were expressed as GST fusion proteins in BL21 cells. The levels of GTP-bound RhoA, Rac and Cdc42 in cell lysates were measured as described previously [6, 21] .
Supplementary material
Supplementary material including production of cell lines, figures depicting the effect of calpeptin on ERK activity and cell morphology and a proposed model for Shp-2-mediated regulation of RhoA, is available at http://current-biology.com/supmat/supmatin.htm.
